Compare Nutrien Ltd (NTR) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nutrien Ltd trades at $70.38 (market cap $33.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: Nutrien Ltd is far larger — about 4.5× Spyre Therapeutics Inc. Common Stock's market cap, and Nutrien Ltd pays a 3.15% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 60 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NTR | SYRE | |
|---|---|---|
Market Cap | $33.39B | $7.35B |
Volume | 2,147,139 | 1,624,631 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $108.92 |
52-Week Low | $53.64 | $22.18 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $45.20B | $6.35B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.68, up 2.47% with mixed technical signals showing bearish momentum but oversold conditions. The company reported Q2 2026 earnings miss ($2.61 vs $2.70 expected) but maintains stable revenue growth projections. Strong institutional interest continues with BlackRock acquiring a $220 million position in Q2 2026, while analyst consensus remains positive with a $77.29 price target representing 11% upside potential.
The fertilizer producer faces near-term headwinds from potential Belarus potash imports but benefits from structural North American gas advantages. While technical indicators suggest caution, fundamental valuation metrics (P/E 14.11, P/S 1.19) appear reasonable given the company's market leadership position and improving profitability trends from 2024 lows.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
